Nipro Corporation

Makoto Sato

Toshiya Kai

Kazutaka Fujiki

Kazuyuki Yamamoto

Shinji Takeoka

Eishun Tsuchida

Naohisa Katayama

Teruyuki Komatsu

Masaki Otagiri

Hiroaki Kato

Takao Okada

Yukio Nakamura

Hiromi Sakai

Shunzo Yamashita

Yoshinori Kida

Yukari Imamura

Ippei Fukutomi

Yoshimichi Fujiyama

Junichi Yokoe

Ryohei Namba

Yohei Hoashi

Yasuhiro Tsutsui

Takeo Kikuchi

Yuko Azuma

Ippei Hukutomi

Keitaro So

Tatsuaki Miyaji

Tamaki Murayama

Hisae Saito

Hideaki Murata

Takashi Katsumata

A pharmaceutical composition containing an artificial oxygen carrier, which has high oxygen carrying efficiency; and has a required colloid osmotic pressure, an appropriate crystalloid osmotic pressure, pH, and electrolyte balance. The composition is prepared by appropriately adding at least one substance selected from the group consisting of a compound capable of providing a colloid osmotic pressure, an electrolyte, a saccharide, an amino acid, an antioxidant, a pH adjuster, and an isotonizing agent to a preparation including a liposome-encapsulated hemoglobin in which a hemoglobin is encapsulated in a liposome or to a preparation including a conjugate of a porphyrin-iron complex and albumin.

Pharmaceutical composition containing artificial oxygen carrier

This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content. There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.

Stabilized albumin preparations

A bioabsorbable release-sustaining pharmaceutical formulation using a biodegradable release-sustaining base material which can prevent an effective component drug from being released too rapidly just after administration of the formulation and then allow continued release of the drug for at least one month at a defined rate, is provided. For the biodegradable release-sustaining base material, a lactic acid-glycolic acid copolymer (PLGA) with an adjusted distribution in molecular weight is used.

Bioabsorbable pharmaceutical formulation

The present invention provides a method of producing a complex of albumin and a deoxy form metal complex having a porphyrin structure, which includes mixing albumin and a metal complex having a porphyrin structure under a gas atmosphere substantially free of carbon monoxide and oxygen, as a method of producing an artificial oxygen carrier containing a complex of albumin and a metal complex having a porphyrin structure, under a deoxidation (nitrogen, other inert gases) atmosphere without using carbon monoxide.

Artificial oxygen carrier and production method thereof

A solid preparation for dialysis for preparing a double preparation type sodium bicarbonate solid preparation for dialysis in which there is no fear that a sugar component is decomposed or colored, and which can maintain stability and is also excellent in content homogeneity and a process for producing the same. The solid preparation for dialysis is a mixture of a first composition composed of core particles including sodium chloride and a coating layer containing one or more electrolytes, a second composition composed of core particles including a sugar that is covered with a coating layer comprising the same sugar or a different sugar, and an acid.

Solid preparation for dialysis and process for producing the same

An albumin preparation that prevents onset of hepatic encephalopathy caused by conventional amino acid preparations and enhances an effect of improving the symptoms is provided. The albumin preparation containing amino acids is characterized in that a content of albumin is 0.01 to 1.0 w/v %, a content of plurality of amino acids containing branched amino acid is 5 to 10 w/v %, a content of the branched amino acids is equal to or more than 30 w/w % on the basis of the content of total amino acids and further, the Fischer ratio (branched amino acid/[phenylalanine+tyrosine] (molar ratio)) is equal to or more than 20.

Amino acid-containing albumin preparation

The present invention provides a plastic container containing albumin solution and a packaged plastic container containing an albumin solution. The plastic container containing an albumin solution having an albumin concentration of 1 to 500 mg/ml, has at least one inlet/outlet for a liquid, and has a water vapor permeability of 1.5 g/m /day&middot;1013.25 hPa or less when the vapor permeability is measured at a pressure of 1013.25 hPa per surface area of 1 m for 24 hours at a temperature of 25&deg; C. and at a relative humidity of 60%. The plastic container containing an albumin solution can be packaged with an outer packaging material to provide the packaged plastic container.

Plastic container containing albumin solution

A nutrient infusion preparation comprises a fat emulsion essentially consisting of fat particles having a mean particle size of 0.003 to 0.100 &mgr;m and a dispersion medium, and a solution containing electrolytes and amino acids. Also the nutrient infusion preparation comprises a fat emulsion (A) consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 &mgr;m and a dispersion medium, and a solution (B) containing electrolytes and/or amino acids. A container having a plurality of chambers which are isolated from each other by partitions capable of being easily opened, whose respective chambers contain the fat emulsion (A) and said solution (B) and optionally a solution (C) containing saccharides. The infusion preparation of the present invention supplies various nutrient components including fatty acids required biologically to patients and enables amelioration or prevention of essential fatty acid deficiencies during TPN therapy. Further, the infusion preparation enables visual identification of insoluble foreign bodies present in an infusion container and can be administered to patients through a sterilization filter.

Nutrient infusion preparation

A solid preparation for dialysis for preparing a double preparation type sodium bicarbonate solid preparation for dialysis in which there is no fear that a sugar is decomposed or colored, and which can maintain stability and also is excellent in content homogeneity and a process for producing the same. The solid preparation for dialysis is a mixture of a first composition composed of core particles including sodium chloride that are coated with a coating layer containing one or more electrolytes, a second composition composed of core particles including a sugar that are covered with a coating layer containing one or more electrolytes, and an acid.

A one-pack solid pharmaceutical composition for dialysate containing sodium bicarbonate which can prevent the reactions between sodium bicarbonate and acetic acid and between sodium bicarbonate and electrolytes, and is excellent in long term storage stability is provided. The solid pharmaceutical composition for dialysate containing sodium bicarbonate is a mixture of an agent A containing sodium chloride, calcium chloride, magnesium chloride, potassium chloride, sodium acetate and acetic acid and an agent B containing sodium bicarbonate coated with sodium acetate.

Solid pharmaceutical composition for dialysate containing sodium bicarbonate and a process for producing the same

Growing community of inventors

Osaka, Japan

Makoto Sato